文献速递关节外科

酮咯酸在初次全髋关节置换术中的安全性:逾7000例分析

Safety of Ketorolac in Primary Total Hip Arthroplasties: An Analysis of Over 7,000 Cases.
PubMed 文献 · J Arthroplasty · 2026-07-28

该回顾性队列分析纳入了2011至2021年间7,211例初次全髋关节置换术(THA),评估围手术期酮咯酸使用与术后急性肾损伤(AKI)的关联。结果显示,酮咯酸使用(35%病例,中位累积剂量30 mg)与AKI风险增加无关(OR 0.8;P = 0.08),且不因给药途径而异;慢性肾病(CKD)是AKI的独立危险因素(OR 4.1;P < 0.001)。

要点

  • 围手术期酮咯酸不增加全髋关节置换术后急性肾损伤风险(OR 0.8;P = 0.08)。
  • 慢性肾病是术后AKI的独立危险因素(OR 4.1;P < 0.001)。
  • 无CKD患者使用酮咯酸与AKI风险降低相关(OR 0.6;P = 0.03)。

核心结论

  • 围手术期使用酮咯酸不增加术后急性肾损伤风险,且与给药途径无关。
  • 慢性肾病、男性、BMI升高、术中输血及高血压病史是术后AKI的独立危险因素。

研究设计与样本

  • 回顾性队列研究,分析2011至2021年间7,211例初次全髋关节置换术住院病例。
  • AKI依据改善全球肾脏病预后组织(KDIGO)标准定义,采用多因素logistic回归调整人口学与临床协变量。
  • 亚组分析按有无慢性肾病(CKD)分层,分别占15%和85%。

主要发现

  • AKI发生率为3.4%。
  • 酮咯酸使用与AKI风险无关(OR 0.8;P = 0.08),各给药途径OR均小于1且P > 0.05。
  • 无CKD患者中,酮咯酸使用与AKI风险降低相关(OR 0.6;P = 0.03)。
  • CKD患者中,酮咯酸使用与AKI风险无关(OR 1.1;P = 0.80)。
  • 其他独立危险因素包括术中输血(OR 4.4;P < 0.001)、新发房颤(OR 3;P < 0.001)、高血压病史(OR 2.2;P < 0.001)、男性(OR 1.4;P = 0.047)、BMI每增加1单位(OR 1.04;P < 0.001)。

关键数值与推荐

  • 酮咯酸围手术期使用率为35%(25%关节周围浸润镇痛,7%静脉给药,3%两者兼用)。
  • 酮咯酸中位累积剂量为30 mg(范围15至90 mg)。
  • 平均年龄66岁,平均BMI 31,女性占51%。

临床怎么用

  • 在初次全髋关节置换术围手术期可考虑使用酮咯酸镇痛,无需过度担忧AKI风险。
  • 对合并慢性肾病、高血压、男性、BMI升高或需术中输血的患者,应加强术后肾功能监测。

局限性

  • 回顾性研究设计,证据等级为III级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ketorolac is commonly utilized perioperatively in primary total hip arthroplasty (THA), either intravenously or via periarticular infiltration analgesia. While effective for pain control, concerns remain regarding its potential to cause acute kidney injury (AKI), particularly in patients who have chronic kidney disease (CKD). This study evaluated the association between perioperative ketorolac administration and postoperative AKI, stratified by baseline renal function and administration route. METHODS: We retrospectively analyzed 7,211 inpatient THAs performed between 2011 and 2021. An AKI was defined according to Kidney Disease: Improving Global Outcomes criteria. Multivariable logistic regressions evaluated the association between perioperative ketorolac administration and in-hospital AKI, adjusting for demographic and clinical covariates. Subgroup analyses were conducted for patients who had (15%) and did not have (85%) preexisting CKD. Ketorolac was administered perioperatively in 35% of cases (25% periarticular infiltration analgesia, 7% intravenously, and 3% both) with a median cumulative dose of 30 mg (range, 15 to 90 mg). The mean age was 66 years, mean body mass index (BMI) 31 and 51% were women. RESULTS: An AKI occurred in 3.4% of cases. Ketorolac use was not associated with increased AKI risk (odds ratio (OR) 0.8; P = 0.08), regardless of administration route (all OR less than 1; all P > 0.05). Chronic kidney disease was an independent risk factor for the development of AKI (OR, 4.1; P < 0.001). In patients who did not have CKD, ketorolac use was associated with a decreased risk of AKI (OR, 0.6; P = 0.03) and not associated with an increased or decreased risk in those who have CKD (OR, 1.1; P = 0.80). Additional independent risk factors for AKI included intraoperative transfusion (OR, 4.4; P < 0.001), new-onset atrial fibrillation (OR, 3; P < 0.001), history of hypertension (OR, 2.2; P < 0.001), men (OR, 1.4; P = 0.047), and elevated BMI (OR, 1.04 per unit increase, P < 0.001). CONCLUSIONS: Perioperative ketorolac use does not elevate the postoperative AKI risk, regardless of administration route. Risk factors for AKI include preexisting CKD, men, elevated BMI, need for intraoperative transfusion, and history of hypertension. LEVEL OF EVIDENCE: III, retrospective cohort study.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Meissner N, Bonakdarhashemi M, Leung N, et al. Safety of Ketorolac in Primary Total Hip Arthroplasties: An Analysis of Over 7,000 Cases. J Arthroplasty. 2026. PMID: 42520993. doi:10.1016/j.arth.2026.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。